BIO-RAD LABORATORIES INC

For the period ended Mar 31, 2024. Filed May 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders' Equity

(In thousands)

	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity
Balance at December 31, 2023	$3	$449,075	$(632,536)	$9,260,629	$(336,038)	$8,741,133
Net income	—	—	—	383,916	—	383,916
Other comprehensive loss, net of tax	—	—	—	—	(89,933)	(89,933)
Stock compensation expense	—	15,262	—	—	—	15,262
Purchase of treasury stock	—	—	(4,702)	—	—	(4,702)
Reissuance of treasury stock	—	(1,710)	7,215	—	—	5,505
Excise tax on stock repurchase	—	—	(47)	—	—	(47)
Balance at March 31, 2024	$3	$462,627	$(630,070)	$9,644,545	$(425,971)	$9,051,134

	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity
Balance at December 31, 2022	$3	$447,454	$(263,586)	$9,898,203	$(466,822)	$9,615,252
Net income	—	—	—	68,962	—	68,962
Other comprehensive income, net of tax	—	—	—	—	58,470	58,470
Stock compensation expense	—	16,608	—	—	—	16,608
Reissuance of treasury stock	—	(660)	5,290	(206)	—	4,424
Balance at March 31, 2023	$3	$463,402	$(258,296)	$9,966,959	$(408,352)	$9,763,716

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.